Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Endocr Relat Cancer. 2019 Jan 1;26(4):425–436. doi: 10.1530/ERC-19-0011

Figure 5. In vivo efficacy of combined palbociclib and omipalisib treatment.

Figure 5.

A, NSG mice carrying THJ16T xenografts were treated with vehicle, 50mg/Kg/day palbociclib, 0.3mg/Kg/day omipalisib, or combination. B, mice carrying THJ16T xenografts were treated with combined drugs as in (A) starting when tumors had reached 500mm3. C, immunohistochemical detection of Ki67 in sections from tumors treated as indicated. D, TUNEL assay on sections from tumors treated as indicated. Bar: 100μm.